Induction Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) in Caucasian Patients with Multiple Myeloma: A Single Center Experience

Normann Steiner, Stephanie Riehl, David Nachbaur, Wolfgang Willenbacher, Gunther Gastl and Eberhard Gunsilius

Department of Internal Medicine V (Hematology and Medical Oncology), Innsbruck Medical University, Anichstr. 35, A-6020 Innsbruck, Austria

*Corresponding author: Eberhard Gunsilius, Professor, Department of Internal Medicine V, Innsbruck Medical University, Anichstr. 35, A-6020 Innsbruck, Austria, Tel: +43 5125040; Fax: +43 512504 25615; E-mail: eberhard.gunsilius@i-med.ac.at

Received date: Jun 10, 2015, Accepted date: Aug 14, 2015, Publication date: Aug 18, 2015

Abstract

Objective: In clinical trials, the combination of bortezomib, thalidomide, and dexamethasone (VTD) has shown excellent results as induction treatment in patients with multiple myeloma. However, "real-life" data in unselected Caucasian patients are lacking.

Methods: We retrospectively analyzed 41 patients treated with VTD between 2005 and 2014.

Results: Post induction, the overall response rate was 78%, with very good partial response (≥VGPR) in 54% and near complete/complete responses (nCR/CR) in 17% of the patients respectively. For patients proceeding to autologous stem cell transplantation (ASCT), post-transplant rates were 96% ≥ VGPR and 48% nCR/CR. Median progression free survival (PFS) was 24 months and the estimated 1-year and 2-year overall survival (OS) rates were 95% and 76%, respectively. Subgroup analyses revealed significantly longer OS and PFS in patients with a ≥ VGPR as first response status compared to those with a < VGPR (OS 44 vs. 25 months (p=0.036); PFS 29.5 vs. 16 months (p=0.011)], as well as in patients who underwent ASCT compared to not transplanted patients [OS 41 vs. 23.5 months (p=0.002); PFS 28 vs. 23 months (p=0.003)]. In 6 patients (15%) therapy was switched to another regimen due to lack of response (< PR, n=4), cardiac decompensation (n=1) or prolonged neutropenia (n=1). Non-hematological grade III/IV toxicities were peripheral neuropathy (2%), infections (7%), herpes zoster (5%), and thromboembolic events (2%). Dose reductions of thalidomide and/or bortezomib were necessary in 24% of the patients because of peripheral neuropathy.

Conclusion: The VTD regimen was found to be a highly effective and well tolerated induction regimen for multiple myeloma patients outside clinical trials.

Keywords: VTD; ASCT; Multiple myeloma; Induction therapy; Toxicity

Introduction

The implementation of novel drugs, such as bortezomib, thalidomide, and lenalidomide into induction regimens before high-dose melphalan treatment (HDT) and autologous hematopoietic stem cell transplantation (ASCT) has improved the survival of patients with multiple myeloma (MM) [1,2]. The three drug combination of bortezomib, thalidomide and dexamethasone (VTD) has shown particularly high response rates, as well as the potential to even achieve deep molecular remissions, and does not impair the mobilization and collection of hematopoietic stem cells [%3,4]. The aim of this retrospective single center study was to evaluate the efficacy and toxicity of VTD as an induction therapy for MM outside a clinical trial in Caucasian patients.

Patients and Methods

Between October 2005 and June 2014, 41 adult patients aged between 35 and 77 years, identified by a search in the local database fraction of the Austrian Myeloma Registry, with symptomatic MM requiring treatment according to the International Myeloma Working Group (IMWG) criteria [5], received induction therapy with VTD, consisting of bortezomib 1.3 mg/m² intravenously on days 1, 4, 8, and 11, oral dexamethasone 40 mg on days 1, 2, 4, 5, 8, 9, 11 and 12, and oral thalidomide 100 mg daily in the evening.

All patients received low-molecular weight heparin and oral antiviral prophylaxis. After three to four cycles of VTD, peripheral blood progenitor cells (PBPC) were harvested after priming with G-CSF 2 x 10 μg/kg over five days in patients scheduled for high-dose therapy (mean of collected stem cells 7.22 x 10⁸ /kg bodyweight) without additional chemotherapy. Thalidomide was omitted in the last cycle before PBPC mobilization to optimize stem cell yield [6]. For these patients consolidation treatment consisted of 200 mg/m² melphalan followed by reinfusion of PBPC. Routinely, no further antimyeloma treatment was given. Transplant ineligible patients received VTD if a rapid response was required, e.g. due to renal insufficiency.

Sampling and evaluation of patients’ data was approved by the local institutional ethics committee (vote number: UN3252) in accordance with the principles of the Declaration of Helsinki.

The first response assessment was performed after three cycles of VTD according to International Uniform Response Criteria for MM [7] with the additional response category of nCR, defined as complete disappearance of monoclonal protein on electrophoresis but positive
immunofixation [8]. Toxicities were graded according to the “Common Terminology Criteria of Adverse Events” (CTCAE v4.03) [9].

Patients were allocated to high-risk or standard-risk groups according to IMWG criteria [10]. High-risk cytogenetics were defined as t(4;14), t(14;16) and/or del17p, all by fluorescence in-situ hybridization (FISH) analysis of myeloma cells.

Statistical evaluation was performed using GraphPad PrismTM software for Windows. All tests of statistical significance were two-sided. Unpaired t-test and survival analysis (Log rank-test) were used to identify differences between two groups.

Results

Patient characteristics

41 patients were treated with VTD. Table 1 summarizes the relevant clinical data and disease characteristics. Data on cytogenetic aberrations, detected by FISH on bone marrow plasma cells, were available and informative in 71%; 9 patients (22%) had high-risk cytogenetics with t(4;14), t(14;16) and/or del17p.

Table 1: Clinical data and disease characteristics of the patients.

|                          | N = 41 | %      |
|--------------------------|--------|--------|
| Age at diagnosis         |        |        |
| Median age               | 58     | 42     |
| Range                    | 35-77  | 42     |
| Sex                      |        |        |
| Male                     | 29     | 71     |
| Female                   | 12     | 29     |
| ISS                      |        |        |
| I                        | 16     | 39     |
| II                       | 12     | 29     |
| III                      | 13     | 32     |
| Immunoglobulin isotype   |        |        |
| IgG                      | 24     | 59     |
| IgA                      | 5      | 12     |
| IgM                      | 3      | 7      |
| LC                       | 9      | 22     |
| Karyotype                |        |        |
| Normal                   | 8      | 20     |
| Aberrant                 | 28     | 68     |
| Not reported             | 5      | 12     |
| Cytogenetic risk group (by FISH) | 9  | 22 |
| High risk*               | 9      | 22     |
| Standard risk            | 27     | 66     |

Table 1: Clinical data and disease characteristics of the patients.

High response to VTD-induction therapy and comparison before and after ASCT

Table 2a shows the results of VTD-induction therapy. The median number of VTD-cycles applied was 3 (1-6 cycles). A ≥VGPR was achieved in 54% (n=22) of the patients and 24% (n=10) reached a partial response (PR). A minor response (MR) was achieved in 1 patient and a stable disease (SD) in 3 patients (7%), respectively, whereas in 5 patients the disease progressed. Table 2b shows the response rates of patients after VTD-induction therapy compared to the results of other VTD-trials [11-15].

In 28 patients (68%) PBPC were collected. The mean number of collected CD34+ cells was 7.22 x 10^6/kg bodyweight (range 2.13 x 10^6–26 x 10^6/kg). 25 patients received HDT and ASCT. The median of VTD-cycles before ASCT was 4. 16 patients (39%) did not proceed to ASCT due to age (n=4; 10%), comorbidity (n=5; 12%), mycobacterial infection (n=1; 2%) or insufficient response (<PR, n=6; 15%). Post-induction, 64% of the transplant eligible 25 patients reached a ≥VGPR, thereof 12% a CR (n=3), and 36% reached a PR (n=9). Three months after ASCT the ORR was 100% with a ≥VGPR in 96% of the patients 48% CR/nCR (n=12), 48% VGPR (n=12) and 1 PR.

Table 2a: Response rate after VTD-induction therapy according to the International Myeloma Working Group response criteria [7].

| References | Patient(s) (n) | ORR (%) | ≥nCR (%) | ≥VGPR (%) | PR (%) | MR/SD (%) |
|------------|----------------|---------|----------|-----------|--------|-----------|
| Our patients | 41             | 78      | 17       | 54        | 24     | 10        |
| Cavo et al. [11] | 236          | 93      | 31       | 62        | 31     | 7         |
| Rosinol et al. [12] | 130          | 85      | 35       | 60        | 25     | 6         |
| Moreau et al. [13] | 100          | 88      | 31       | 49        | 39     | NR        |
| Kaufman et al. [14] | 44           | 91      | 20       | 57        | 34     | 5         |
| Buda et al. [15] | 43            | 91      | 30       | 51        | 40     | 7         |

Table 2b: Response rate after VTD-induction therapy compared with the results of other VTD-trials.

ORR: Overall Response Rate (≥PR); CR=Complete Response; nCR=Near Complete Response; VGPR: Very Good Partial Response; PR: Partial Response; MR: Minor Response; PD: Progressive Disease
35 patients were evaluable for OS and PFS. 6 patients (15%) discontinued VTD-induction due to lack of response (<PR, n=4), cardiac decompensation (n=1) or prolonged neutropenia (n=1). At data cut-off (May 31, 2014), the median follow-up was 32 months (range 7-88). The median PFS was 24 months. The median OS has not been reached, the estimated 1-year and 2-year OS rates were 95% and 76%, respectively. An analysis of PFS and OS according to the first response status revealed significant differences between patients with a ≥VGPR (n=20; 57%) and patients with <VGPR (n=15; 43%) [OS 44 vs. 25 months (p=0.036); PFS 29.5 vs. 16 months (p=0.011)]. Significant differences in OS and PFS were also evident in patients who underwent ASCT (n=25; 71%) and patients who did not undergo ASCT (n=10; 29%) [OS 41 vs. 23.5 months (p=0.002); PFS 28 vs. 23 months (p=0.003)]. Overall, there was no significant difference regarding OS and PFS between cytogenetic high-risk (n=7; 20%) and standard-risk patients (n=24; 69%). Median OS was 29 months in the high-risk group vs. 40 month in the standard-risk group (p=0.27), median PFS was 21 months (high-risk) vs. 28 months (standard-risk; p=0.17). Results are shown in Figure 1A-C.

### Toxicities and adverse events associated with therapy

Toxicities are shown in Table 3a. Peripheral neuropathy (PN) was the most common adverse event. Severe infections as defined by CTCAE v4.03 occurred in 3 patients (Mycobacterial infection n=1, febrile neutropenia n=2). Two patients developed a herpes zoster reactivation despite adequate prophylaxis. Hematological toxicities grade III/IV were thrombocytopenia (n=5) and neutropenia (n=2). 2 patients had a thromboembolic event, of which one were grade III/IV (catheter-associated thrombosis of the vena subclavian n=1, ischemic stroke n=1). Table 3b shows the side effects of the patients compared to the results of other VTD-trials [11-14].

Dose reductions of thalidomide and/or bortezomib were necessary in 10 patients (24%) because of PN.

### Table 3a: Adverse events associated with VTD therapy.

| Grade III/IV | All grades |
|--------------|------------|
| N=41 | % | N=41 | % |
| Herpes zoster | 2 | 5 | 2 | 5 |
| Infections (bacterial) | 8 | 20 | 3 | 7 |
| Peripheral neuropathy | 18 | 44 | 1 | 2 |
| Neutropenia | 8 | 20 | 2 | 5 |
| Thrombocytopenia | 6 | 15 | 3 | 7 |
| Thromboembolic events | 2 | 5 | 1 | 2 |
| Nausea | 1 | 2 | 0 | 0 |

NR: Not Reported.

### Table 3b: Grade III/IV toxicities associated with VTD-induction therapy - Comparison to the results of other VTD-trials.

| References | Infection s (%) | Peripheral neuropathy (%) | Neutropenia (%) | Thrombo - cytopenia (%) | Thrombo - embolic events (%) |
|------------|----------------|---------------------------|-----------------|------------------------|----------------------------|
| Our patients | 7 | 2 | 5 | 7 | 2 |
| Cavo et al. [11] | 3 | 10 | NR | NR | 3 |
| Rosinol et al. [12] | 21 | 14 | 10 | 8 | 12 |
| Moreau et al. [13] | 10 | 3 | 0 | 3 | 2 |
| Kaufman et al. [14] | 0 | 9 | 0 | 2 | 4 |

NR: Not Reported.
immunomodulatory drugs) seem to be most logical therapeutic backbones.

The aim of this retrospective study was to evaluate the response, side effects, and the outcome of patients with MM using the VTD-protocol as induction therapy in unselected Caucasian patients outside a clinical trial, thereby reflecting "real life" myeloma treatment. Comparing our results to published data from clinical trials and retrospective studies in which VTd was given as induction regimen [11-15] (Table 2b), our data confirm that the VTD protocol is a very effective induction regimen outside clinical trials. The observed ORR in our cohort was 78%, with 17% of the patients reaching a CR/nCR, and 37% of the patients reaching VGPR (54% ≥VGPR). These are impressive results in an unselected patient cohort, due to excellent disease control in a short period of time, which is in accordance with published data on VTD-induction therapy [14].

For patients proceeding to ASCT, 12% of the patients reached a CR and 64% a ≥VGPR. After ASCT, all but one patient (96%) reached ≥VGPR, thereof 48% a CR/nCR. Optimal response is considered a prerequisite for long-term disease control [16]. Our post-transplantation results are similar to that of the large, randomized phase 3 GIMEMA trial, which compared VTd and TD as a pre-transplantation induction therapy followed by double ASCT and further consolidation in patients with newly diagnosed MM [11]. In this trial, 31% of the patients who received induction therapy with VTD reached a CR/nCR, and 62% achieved ≥VGPR. After ASCT-consolidation, rates of CR/nCR and ≥VGPR were 52% and 79%, respectively. As the GIMEMA trial used further post-transplantation VTD consolidation only long-term results will proof the potential additional benefit of this therapeutic element. Furthermore, Ladetto [17] and co-workers reported persistent molecular remission with this approach arguing for minimal residual disease (MRD) triggered allocation of therapies in future clinical trials. Comparing VTd with TD and VBMC/PB/B, also the PETHEMA/GEM study showed similar results in the VTD arm as we observed in our patients after ASCT [12]. The rate of CR increased from 35% after VTd-induction therapy to 46% after ASCT. Of note, our study represents data of an unselected patient cohort.

In our patients the median PFS was 24 months. The median OS from initiation of VTd induction had not been reached after a median follow-up of 32 months, and the estimated 1-year and 2-year OS rates were 95% and 76%, respectively. These data are comparable to the retrospective data of Kaufman et al. (median follow-up 25 months; PFS 27.5 months; 1-year OS rate 95%, 2-year OS rate 82%) [14]. Several studies suggest that the quality of response after induction therapy is a predictor for survival time [18-21]. Consistently, our data show significant differences in OS and PFS between patients with initial response ≥VGPR and <VGPR (figure 1b).

In general, the VTD-regime is well tolerated [11]. The most common non-hematological toxicity we observed was PN in 44% of the patients (all grades n=18, grade III n=1), which is in accordance to published toxicity data. However, only one patient (2%) developed a PN grade III and no grade IV PN was observed. In the GIMEMA trial 10% of the patients had PN grade III/IV [11]. Kaufman et al. reported similar results regarding the overall incidence of PN as we observed (55%) [14]. In table 3a, additional grade III/IV toxicities associated with VTd-induction therapy are shown. A dose reduction was necessary in 24% of the patients due to development of PN. The Intergroupe Francophone du Myelome (IFM) conducted a phase 3 trial comparing a reduced dose of bortezomib (1 mg/m² i.v. on days 1, 4, 8 and 11 of a 3 week cycle) and thalidomide (100 mg/day) plus dexamethasone (vtD) with the standard VD-regimen [13]. They could show that in spite of adding thalidomide to the vD-group, there were less cases of PN noticed as in the VD-regime group [13]. Another strategy to improve tolerability of bortezomib was published first in the MMY-3021 Phase III trial [22], where subcutaneous administration of bortezomib in patients with relapsed MM showed a non-inferior efficacy (ORR after induction in both groups 42%) and low rates of PN compared to the intravenous administration of bortezomib (PN all grades: s.c. 38% vs i.v. 53%). These results are confirmed by a number of other prospective and retrospective studies with subcutaneous bortezomib in diverse settings (Cavallo et al. [23]).

In summary, our data confirm VTd as an effective and well tolerated induction therapy in unselected Caucasian patients with MM outside clinical trials. Both tolerance (bortezomib s.c.) as well as applicability of the regimen in elderly patients (bortezomib s.c./weekly) might be further optimized to achieve even better treatment results in more myeloma patients.

Acknowledgements

This work was supported by an educational grant from Janssen Austria for data analysis and the diploma thesis of Stephanie Riehl. Patients were identified by Mag. Roman Weger from the Austrian Myeloma Registry. Author's contributions to this work: Steiner and Riehl performed the data analysis & interpretation. Gunstlits, Gastl, Nachbaur, Willenbacher and Steiner wrote the paper.

Conflict of Interest

The authors declare no financial conflict of interest.

References

1. Attal M, Harousseau JL, Stoppa AM, Sotto JF, Fuzibet JG, et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 335: 91-97.
2. Child JA, Morgan GI, Davies FE, Owen RG, Bell SE, et al. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348: 1875-1883.
3. Barlogie B, Anaisse E, Van Rhee F, Haessler J, Haggarty K, et al. (2005) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 138: 176-185.
4. Pineda-Roman M, Zangari M, Van Rhee F, Anaisse E, Smyronifka J, et al. (2008) VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 22: 1419-1427.
5. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammapathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121: 749-757.
6. Auer HW, Mazarella L, Cook L, Saydlo R, Saltarelli F, et al. (2011) High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. Bone Marrow Transplant 46: 364-367.
7. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, et al. (2006) International uniform response criteria for multiple myeloma. Leukemia 20: 1467-1473.
8. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617.
9. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
10. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, et al. (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23: 2210-2221.
11. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, et al. (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376: 2075-2085.
12. Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, et al. (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120: 1589-1596.
13. Moreau P, Avet-Loiseau H, Pacon T, Attal M, Tiab M, et al. (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118: 5752-5758.
14. Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, et al. (2010) Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer 116: 3143-3151.
15. Buda G, Orzicuolo E, Carulli G, Galimberti S, Ghio F, et al. (2013) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients. Acta Haematol 129: 35-39.
16. Ludwig H, Bekiac M, Bladé J, Boccadoro M, Cavenagh J, et al. (2010) Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 15: 6-25.
17. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, et al. (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28: 2077-2084.
18. Cavo M (2006) Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20: 1341-1352.
19. van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, et al. (2007) Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92: 1399-1406.
20. Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, et al. (2010) Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 116: 3743-3750.
21. Harousseau JL, Attal M, Avet-Loiseau H (2009) The role of complete response in multiple myeloma. Blood 114: 3139-3146.
22. Moreau P, Pylypenko H, Grosicki S, Karamanesh I, Leleu X, et al. (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12: 431-440.
23. Lamm W, Drach-Schauer B, Eder S, Drach J (2013) Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. Oncology 85: 223-227.